‘Poop Pills’ Show Promise for Severe Peanut Allergy, Early Research Suggests
A recent clinical study has revealed that fecal microbiome transplantation (FMT), colloquially known as “poop pills,” may enhance peanut tolerance in adults suffering from peanut allergies. Published in *Science Translational Medicine*, the research indicates that gut bacteria from healthy donors can potentially reduce the severity of peanut allergies in some individuals.
In this small-scale trial, 15 participants were monitored for changes in their tolerance to peanuts after receiving frozen fecal transplants from healthy individuals. The study found that six of these participants showed increased tolerance to peanuts. The trial was conducted in two phases. In the first phase, ten participants received FMT over one or two days and were evaluated four months later, with three out of ten reporting improved tolerance. The second phase involved five participants who had taken antibiotics prior to receiving FMT; three out of these five also exhibited increased peanut tolerance.
Dr. Rima Rachid, one of the study’s authors, emphasized the significance of these findings, suggesting that this is the first study to show how microbiome-based therapies can influence food allergies. She noted that FMT led to an increase in regulatory T cells, which are crucial for immune system regulation, among those who showed improved tolerance.
While the results are encouraging, experts caution that it is premature to recommend FMT as a standard treatment for peanut allergies. Dr. Mohammad Bakhtiar, a clinical lead at Medical Express Clinic, highlighted the limitations of the study due to its small sample size and the need for further research. He stated, “This study should be viewed as an early signal, not a definitive change in practice.”
Exploring the role of gut bacteria further, researchers transplanted microbiomes from participants who experienced increased peanut tolerance into mice. The mice demonstrated protection against peanut allergies, which was attributed to the presence of an enzyme called bile salt hydrolase produced by Bacteroides bacteria. However, this particular aspect has yet to be tested in humans.
Currently, treatments for peanut allergies mainly include immunotherapy and biologics, with many patients needing to carry epinephrine auto-injectors for emergency situations. While the findings from this study are promising, Rachid clarified that FMT is not yet ready for clinical use. Future research aims to develop a more refined form of FMT known as microbiota transplantation therapy (MTT), which would contain minimal nonmicrobial material. This method has the potential to be stored in home refrigerators and could lead to longer-term solutions if proven effective.
The researchers acknowledge that significant funding and larger-scale trials will be necessary to validate their findings and explore the potential of microbiome-based therapies in treating peanut allergies. If successful, these treatments could become available within the next decade, fundamentally changing the management of peanut allergies and improving the quality of life for those affected. For now, individuals with peanut allergies are advised to continue strict avoidance of allergens and maintain an emergency action plan.
